Graph and download economic data for Producer Price Index by Industry: Pharmaceutical and Medicine Manufacturing (PCU32543254) from Dec 1984 to Sep 2025 about medicines, pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

In 2024, the consumer price index (CPI) of pharmaceutical products in the United Kingdom (UK) was measured at some 133. The CPI is designed to measure changes in the prices of goods that consumers buy. The year 2015 is used as the base year for calculations, and therefore the index in this year measures 100. UK OTC medication market The sales value of the British over-the-counter (OTC) medicines market has generally increased since 2000, amounting to a worth of approximately 4.1 billion British pounds in 2024. The category with the highest sales value among OTC medication in 2024 was pain relief, which accounted for nearly 860 million British pounds worth of sales. Prescribed medication At the same time as the OTC market has been growing, the number of prescription items dispensed also increased during this period. In 2023/24, the number of items dispensed in England showed a record high of 1.11 billion. The average number of prescription items dispensed per month at pharmacies in England came to over 7,100 in 2023/24.

Graph and download economic data for Producer Price Index by Industry: Pharmacies and Drug Retailers: Retailing of All Other Goods (PCU44611044611042) from Jun 2000 to Sep 2025 about medicines, retail, goods, PPI, industry, inflation, price index, indexes, price, and USA.

In the third quarter of 2025, the Consumer Price Index for health products and services in the United Kingdom was 139.4, indicating that, compared with 2015, prices in this sector have increased by 39.4 percent, compared with 39.2 percent for overall prices.

In the last five years, turnover in the pharmaceutical industry has fallen by an average of 1.9% per year. Turnover did increase during the coronavirus pandemic, as the industry recorded stable demand at home and abroad and pharmaceutical supply chains remained intact despite pandemic-related shocks. Nevertheless, the pharmaceutical industry was exposed to high cost pressure in the years that followed. For example, chemical goods became massively more expensive in the wake of the energy crisis in 2022. The high prices for energy and primary products have driven up input costs even further in recent years. Procurement risks arose, among other things, from price increases and the lack of advance deliveries from the chemical industry, which cut back on production as a result of the high energy costs. The increased costs could not be passed on in full and had a negative impact on the profit margin. In addition to a decline in demand for vaccines, the economic policy framework, above all the SHI Financial Stabilisation Act, which came into force at the end of 2022 and increased the mandatory manufacturer discount for patented medicines from 7% to 12% for 2023, had a negative impact on the business of industry players. Despite the difficult framework conditions and the continuing crisis in the German economy, sales growth is forecast for 2025. Research expenditure has recently increased. The development and production of biopharmaceuticals is becoming increasingly important. Finally, the export business will also increase again in the current year due to increased demand on the European market. In 2025, industry turnover is expected to reach €95.5 billion, which corresponds to growth of 1.7% compared to the previous year. The producer price for pharmaceutical products should gradually fall again this year. This will allow industry players to generate higher profits again as manufacturing costs fall.It can be assumed that the framework conditions for manufacturers of pharmaceutical products in Germany will continue to prove challenging over the next five years. Due to the extension of the price moratorium on pharmaceuticals until 2026 provided for in the new Savings Act, manufacturers will only be able to pass on inflation-related price increases to a limited extent. In addition, the higher manufacturer discounts act as an additional cost burden and dampen the willingness to invest in the German location. There is growth potential for the industry in the context of digitalisation and automation and the associated development of new business areas. The advancing ageing of society as a result of demographic change, which favours the demand for pharmaceutical products, is an advantage. By 2030, the industry's turnover is expected to grow by an average of 0.5% per year and is therefore likely to reach 97.6 billion euros.

According to Cognitive Market Research, the global Pharmaceutical CXO market size was USD XX million in 2024. It will expand at a compound annual growth rate (CAGR) of 15.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD XX million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.7% from 2024 to 2031.
The CRO category is the fastest growing segment of the Pharmaceutical CXO industry

Market Dynamics of the Pharmaceutical CXO Market:

Key Drivers for the Pharmaceutical CXO Market

Increasing Drug Development Costs and Complexity to Drive Market Growth

The cost of developing new drugs has significantly increased due to the growing complexity of drug development and rigorous regulatory demands. In 2019, the pharmaceutical industry invested $83 billion in research and development (R&D). When adjusted for inflation, this figure is approximately ten times higher than the annual R&D spending of the 1980s. During the twelve months from July 2021 to July 2022, 1,216 products saw price increases that surpassed the inflation rate of 8.5% for that period. On average, the price of these drugs rose by 31.6%. In some cases, drug prices surged by over $20,000, representing a dramatic increase of up to 500%. To manage these escalating costs, pharmaceutical companies are increasingly relying on Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs). These organizations provide specialized expertise and advanced technologies that streamline the drug development process, helping to reduce both costs and time-to-market.

Restraint Factor for the Pharmaceutical CXO Market

Regulatory and Compliance Challenges Will Limit Market Growth

The pharmaceutical industry is highly regulated, and compliance with global and regional regulations can be complex and costly. CROs and CMOs must navigate various regulatory requirements across different markets, which can lead to delays and increased operational costs. Regulatory standards are constantly evolving, and staying compliant with these changes requires continuous updates to processes and systems, adding to operational complexity and costs. Ensuring consistent quality across different CROs and CMOs can be challenging. Variability in quality standards and practices among service providers can impact the overall quality of drug development and manufacturing processes.

Impact of Covid-19 on the Pharmaceutical CXO Market

The urgent need for COVID-19 vaccines and treatments led to a surge in demand for CRO and CMO services. Companies relied heavily on these organizations to expedite clinical trials, scale up production, and ensure rapid development and distribution of vaccines and therapies. The pandemic expanded the scope and scale of clinical trials, including trials for COVID-19 treatments and vaccines, which increased the demand for CROs to manage and execute these trials effectively. The rapid development and approval processes introduced new challenges in maintaining rigorous regulatory standards and quality control, requiring CROs to adapt their practices accordingly.

Opportunity for the Pharmaceutical CXO Market

Growing demand for biologics and specialty drugs will further provide an opportunity for the market

The increasing development and production of biologics, including biosimilars, has significantly provided an opportunity to the demand for specialized Contract Manufacturing Organization (CMO) services. The data reveals that therapeutic areas with biosimilars introduced in the past some years see an average market share of XX%. In the U.S., the presence of bio...

ABSTRACT Price regulation aims to ensure sustainability of pharmaceutical care. Aiming to critically discuss the regulation of pharmaceutical prices in Brazil, we elaborated an essay based on document analysis (2000-2017) of the pharmaceutical economic regulation found at the Medication Regulation Chamber (CMED), journals, theses, and publications of the Legislature and pharmaceutical industry. For 15 years, Act no. 10.742/2003 has established a price ceiling model, comprising maximum prices for medicines and annual readjustments according to a formula defined in law. Model, implementation and formula have all been criticized. The formula links adjustments to the IPCA (general inflation index), adding indexes for production costs, competition, and productivity. The longevity of the model, without regular realignment of the ceiling to actual market prices, as recommended in specialized literature, generates price ceilings detached from reality, which deepen information asymmetries and may support abusive price increases in the future. Prioritization of market efficiency over reduction of information asymmetry in the regulatory model has reduced the strength of consumers in the debate. The current regulatory model has advanced in relation to previous liberalized pricing policies, but further improvement depends on the appropriation of the theme and increasing participation of consumers and health professionals in the regulatory process.

• The global industry was valued at US$ 537.7 Mn in 2022
• It is projected to grow at a CAGR of 5.2% from 2023 to 2031 and reach more than US$ 851.8 Mn by the end of 2031

Global Inflation Devices Market Snapshot

Attribute	Detail
Market Value in 2022	US$ 537.7 Mn
Forecast (Value) in 2031	US$ 851.8 Mn
Growth Rate (CAGR)	5.2%
Forecast Period	2023-2031
Historical Data Available for	2017-2021
Quantitative Units	US$ Mn for Value
Market Analysis	It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape	Market share analysis by company (2022) Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format	Electronic (PDF) + Excel
Market Segmentation	Display Type Analog Inflation Devices Digital Inflation Devices Pressure Capacity 20 ml Inflation Devices 30 ml Inflation Devices 60 ml Inflation Devices Function Balloon Angioplasty Arterial Stent Placement Endoscopy Others Application Coronary Interventions Urology Gastroenterology Peripheral Interventions Others End-user Hospitals Specialty Clinics Ambulatory Surgery Centers
Regions Covered	North America Latin America Europe Asia Pacific Middle East & Africa
Countries Covered	U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico South Africa GCC Countries
Companies Profiled	Atrion Medical BD Lepu Medical Technology (Beijing) Co., Ltd. Merit Medical Systems Translumina Advin Health Care Dolphin Life Science India LLP Boston Scientific Corporation Acclarent, Inc. (Johnson & Johnson MedTech) B. Braun Interventional Systems Inc. CONMED Corporation Cook Medical
Customization Scope	Available upon request
Pricing	Available upon request

View yearly updates and historical trends for US Producer Price Index: Medical Equipment & Supplies Manufacturing. from United States. Source: Bureau of L…

In financial year 2022, the cost of healthcare goods and services, also known as medical inflation, reached approximately **** percent in India. This figure was significantly higher than the general inflation rate in the country. In fiscal year 2023, medical inflation is forecasted to decrease to **** percent.

The health sector in the Netherlands experienced an inflation rate of 5.7 percent in September of 2023, indicating that the prices of the health sector had increased by 5.7 percent compared to the same month of the previous year. The highest inflation rate in this period was recorded in the most recent time period, with an inflation rate of 5.8 percent. February of 2016 registered the largest price fall, with an annual change in CPI of minus three percent.

Global pharmaceutical manufacturers support health outcomes in developed and emerging economies. Rising pharmaceutical spending has been fueled by an aging population, longer life spans and the prevalence of chronic diseases. At the same time, tech and medical breakthroughs are introducing new specialty drugs that fill unmet medical needs but come with a higher price tag. Concerns globally that rising pharmaceutical spending has been driven more by higher prices over higher utilization have created tense regulatory and pricing pressures, most notably the introduction of the Inflation Reduction Act in the US. Manufacturers are also navigating an unprecedented patent cliff, putting billions of revenue on the line over the next decade. This has created a more active M&A space, closely tying traditional pharmaceutical manufacturers to the fast-growing biotechnology space. A complex operating environment has strained growth, leading revenue to fall at a CAGR of 0.9% to an estimated $1.2 trillion over the past five years. Rising spending from emerging economies contributes to the global expansion of pharmaceutical production. Nations like Brazil, Thailand and Turkey (among many others) have significantly increased their healthcare budgets, recognizing the importance of improving domestic medical infrastructure and access to essential medicines. Emerging economies also present growing middle-class populations, leading to a higher demand for more comprehensive healthcare solutions, including pharmaceuticals. Pharma incumbents also capitalize on this shift to mitigate patent expirations in developed markets. Growth of pharmaceutical production in emerging economies has also been significant. India and China, for example, are increasing powerhouses in pharmaceutical manufacturing, leveraging their large, skilled workforces and cost-effective production capabilities to capture a larger share of the global market. This expansion is supported by proactive government policies to strengthen domestic production. Moving forward, pharmaceutical manufacturers globally will continue expanding as they adapt to evolving healthcare needs and tech advancements. An increasing prevalence of chronic diseases and a growing global population will continue to drive demand for effective and affordable treatments. The industry's shift towards digitalization through artificial intelligence, machine learning and blockchain technologies will enhance areas spanning supply chain management to drug development. The industry's central challenge will be navigating regulatory changes and pricing pressures while focusing on innovation and sustainability. In all, revenue will continue expanding at a CAGR of 3.0% to an estimated $1.4 trillion over the next five years.

A challenging supply chain environment and weak consumer spending have challenged pharmaceutical and toiletry goods wholesalers. In recent years, high inflation and rising interest rates have impacted discretionary expenditure patterns, leading to changes in product mix and distribution channels used as weakened purchasing power saw consumers switch prices and retail outlets. Similar to many other wholesalers, cosmetics and toiletry wholesalers are struggling to maintain their position in the face of wholesale bypass. Intensifying competitive pressures are adding to industry challenges and eroding profit margins. At the same time, industry wholesalers have benefited from the dynamic nature of the wider beauty sector, which is continuing to evolve in line with new digital trends and social media platforms that redefine beauty. Emergent health, wellbeing and beauty trends are also stimulating changes as beauty and wellness lines become increasingly blurred. 'Beauty-from-within' trends are equally serving to blur the lines between health and beauty, stimulating product portfolio changes for pharmaceutical and cosmetics wholesalers alike. A constant array of new products, thanks to ongoing upstream product innovations, is also serving to change product mixes. Industry revenue is expected to post annualised growth of 2.4% over the five years through 2025-26, to $8.5 billion. This includes expected growth of 2.5% in 2025-26, supported by higher Pharmac funding levels and improved household discretionary incomes. Rising health consciousness, ongoing product innovations and new technological platforms will drive growth in the coming years. As will New Zealand's ageing population and the rising prevalence of chronic diseases across all age groups, with both variables driving the need for a greater volume and variety of pharmaceuticals. Proposed healthcare reforms to improve access to innovative medicines for New Zealanders are also set to have positive implications for pharmaceutical wholesalers. Overall, industry revenue is forecast to grow at an annualised 1.4% over the five years through 2030-31, to reach $9.2 billion.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Cancer Therapy Products (PCU3254123254121111) from Jun 1981 to Sep 2025 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

Graph and download economic data for Producer Price Index by Industry: Pharmaceutical Preparation Manufacturing: Antacids (PCU325412325412D113) from Dec 2009 to May 2017 about pharmaceuticals, manufacturing, PPI, industry, inflation, price index, indexes, price, and USA.

The global market for single-use inflation devices is experiencing robust growth, driven by the increasing prevalence of minimally invasive surgical procedures and a rising demand for improved patient outcomes. The market is segmented by application (hospitals, clinics, others) and device capacity (20ml, 30ml, 60ml, others). Hospitals currently represent the largest segment, accounting for approximately 60% of the market, owing to their higher procedure volumes and advanced infrastructure. However, the clinics segment is projected to witness the fastest growth rate over the forecast period (2025-2033) due to increasing investment in ambulatory surgical centers and a preference for outpatient procedures. The 30ml capacity devices currently hold the largest market share, reflecting their widespread use in various surgical applications. However, larger capacity devices (60ml and above) are expected to gain traction due to advancements in minimally invasive surgical techniques requiring larger inflation volumes. Key restraining factors include the relatively high cost of these devices and potential regulatory hurdles in certain regions. The competitive landscape is characterized by a mix of established players like Boston Scientific, Medtronic, and B. Braun, and smaller specialized companies, resulting in ongoing innovation and market diversification. North America currently dominates the market, followed by Europe, driven by strong healthcare infrastructure and high adoption rates. However, Asia-Pacific is expected to show significant growth in the coming years fueled by rising disposable incomes and expanding healthcare systems. The projected Compound Annual Growth Rate (CAGR) for the single-use inflation devices market from 2025 to 2033 suggests a steady expansion. This positive outlook is further underpinned by continuous technological advancements leading to improved device designs with enhanced functionalities, improved safety profiles, and better patient outcomes. Furthermore, the increasing preference for single-use devices over reusable ones, owing to infection control concerns and cost-effectiveness in the long run, is a significant market driver. The strategic alliances and acquisitions among industry players are also accelerating market penetration. While regulatory landscape variations across different countries might pose some challenges, the overall market trajectory remains bullish, driven by the underlying demand and consistent market expansions in both developed and emerging economies. Regional variations in market growth are expected, with faster growth anticipated in developing regions such as Asia-Pacific due to increasing healthcare expenditure and rising adoption rates.

In 2020, the inflation rate of the healthcare sector in Indonesia was at approximately **** percent, a decrease in comparison to the previous year. The inflation rate of the healthcare sector in the country was the highest in 2014, at **** percent.

The Balloon-Inflation Device market plays a crucial role in various industries, particularly in healthcare, automotive, and entertainment, where precise inflation control is essential. These devices are widely used to inflate balloons for medical procedures, such as angioplasty, where balloon catheters help in expan

Pharmaceutical, cosmetic and toiletry goods retailers have experienced significant revenue fluctuations in recent years, driven by a range of economic and consumer forces. Early sales surges at the height of the pandemic stemmed from heightened focus on health and hygiene, which increased demand for pharmaceuticals and self-care products. Retailers with robust digital platforms thrived as consumers shifted to online shopping. However, this initial boom was soon tempered by persistent cost-of-living pressures, rising inflation, and the winding back of government assistance, leading to more volatile trading conditions. Industry revenue has climbed at an annualised 2.8% over the five years through 2025-26 to $4.7 billion, including growth of 1.2% in the current year. Competition from department stores, supermarkets and online-only retailers has disrupted the trading landscape for industry retailers. Expanding product ranges have enabled competitors to stock more cosmetics and personal care products, often at competitive prices. Investments in omnichannel retailing, broadening of product mixes toward high-margin and eco-conscious offerings, and continued public health funding have all supported profitability, even as consolidation and store network optimisation have become increasingly common responses to competition. Looking ahead, government funding increases for Pharmac and healthcare initiatives like easier access to medicines and extended prescription periods, are set to lift industry revenue and service diversification, particularly as the population ages and chronic illness rates rise. Easing inflation and falling interest rates should restore some disposable income, which bodes well for discretionary purchases. However, competitive pressures from supermarkets, discount retailers and online-only players will remain fierce, likely further limiting new market entrants and driving consolidation. Opportunities will be strongest for those who innovate—whether by championing ethical and sustainable products, targeting niche and culturally diverse markets or leveraging digital tools and social media to connect with consumers. Ultimately, retailers embracing diversification, omnichannel sales and premium offerings will be best positioned to capture evolving market demand and achieve sustainable growth. Industry revenue is forecast to rise at an annualised 1.2% over the five years through 2030-31 to reach $5.0 billion.

Health and medical insurance companies experienced significant fluctuations in performance in recent years. The onset of COVID-19 led to a substantial increase in healthcare spending in 2020 and 2021, as demand for medical services surged. Consequently, investment in health insurance witnessed a dramatic rise, contributing to robust revenue growth during these years. However, with inflation peaking in 2022, consumer purchasing power diminished, causing households to reduce their spending on health insurance. This factor, coupled with a slowdown in health expenditure growth as the immediate pandemic effects waned, resulted in meager revenue growth for insurers in 2022, a notable deceleration compared to prior years. The industry performed better in 2023 as low inflation enabled consumers to more easily afford health insurance, with revenue then rising significantly in 2024 due to soaring investment income. More broadly, providers have been influenced by slowing healthcare inflation, despite a historically rapid rise in prior decades. For example, from 1970 to 2010, health expenditures skyrocketed, buoyed by substantial innovations. However, recent years have seen this growth plateau. This is attributed to a shift toward less costly innovation, focusing more on pharmaceutical advancements rather than costly healthcare system overhauls. Consequently, providers have faced slower revenue growth. Consolidation has risen as the industry’s largest players have used economies of scale, acquisitions and advertising to take over more of the market. Regardless, internal competition has soared as more providers have entered the industry to capture new revenue streams due to rising short-term health spending and the aging of the US population, constraining profit. Overall, revenue for health and medical insurance companies has swelled at a CAGR of 3.8% over the past five years, reaching $1.5 trillion in 2025. This includes a 2.5% rise in revenue in that year. The industry's landscape is set for further evolution over the next five years. Anticipated steady economic growth, with GDP projected to rise and unemployment to remain low, is likely to bolster health insurance revenue streams, primarily through heightened spending on employer-sponsored and private health plans. However, the potential for economic disruptions, such as the implementation of tariffs, could affect providers’ stability. As the population ages and healthcare demand grows, insurers will seek to tailor their policies to address the needs of an older demographic, necessitating comprehensive services. Overall, revenue for health and medical insurance providers is forecast to expand at a CAGR of 2.7% over the next five years, reaching $1.8 trillion in 2030.